# Olatec Therapeutics

> Olatec Therapeutics is a clinical-stage biopharmaceutical company in New York developing a platform of oral NLRP3 inflammasome inhibitors to treat acute and chronic inflammatory diseases. Its lead compound, dapansutrile (OLT1177), is a selective small-molecule NLRP3 inhibitor that has shown clinical benefit and a clean safety profile across gout, heart failure and a broad range of inflammatory and neuroinflammatory conditions, positioning oral inflammasome blockade as a potential alternative to injectable IL-1 biologics.

- **Founded:** 2003
- **Headquarters:** New York, New York, United States
- **Founders:** Damaris B. Skouras (Founder, Chairman & CEO), Charles A. Dinarello (Co-Chief Scientific Officer & Chairman, Scientific Advisory Board)
- **Team size:** ~14 employees
- **Products:** Dapansutrile (OLT1177), NLRP3 inhibitor platform
- **Notable:** Advanced dapansutrile, an oral selective NLRP3 inhibitor, into Phase 2/3 clinical development., Published Phase 2a gout-flare results in The Lancet Rheumatology with no serious adverse events in 34 patients., Demonstrated activity across 20+ preclinical disease models including arthritis, heart failure, Parkinson's and Alzheimer's.

## Products & services

- **Dapansutrile (OLT1177)** — Lead compound: an orally administered, selective small-molecule NLRP3 inflammasome inhibitor that blocks formation of the NLRP3 inflammasome and reduces pro-inflammatory cytokines IL-1 beta and IL-18. In Phase 2/3 clinical development across gout, Parkinson's disease, type-2 diabetes and melanoma.
- **NLRP3 inhibitor platform** — A pipeline of roughly 40 oral NLRP3 antagonist candidates protected by 180+ patents and patent applications, aimed at indications including arthritis, heart failure, asthma, Alzheimer's, multiple sclerosis and certain cancers.

## Achievements

- Advanced dapansutrile, an oral selective NLRP3 inhibitor, into Phase 2/3 clinical development.
- Published Phase 2a gout-flare results in The Lancet Rheumatology with no serious adverse events in 34 patients.
- Demonstrated activity across 20+ preclinical disease models including arthritis, heart failure, Parkinson's and Alzheimer's.
- Built a portfolio of 180+ patents and patent applications around NLRP3 inhibition.
- Secured a research grant from The Michael J. Fox Foundation for Parkinson's research.

## Latest updates

- **2025-11** — Presented preclinical evidence of disease-modifying activity with dapansutrile in Parkinson's disease studies.
- **2024-07** — Enrolled first patient in a Phase 2 study of dapansutrile in type-2 diabetes.
- **2024-02** — Announced plans to conduct a Phase 2 clinical trial of dapansutrile in patients with early Parkinson's disease.
- **2023-10** — Published preclinical research on oral NLRP3-specific inhibitor dapansutrile in pancreatic ductal adenocarcinoma.

## Links

- Website: https://olatec.com
- LinkedIn: https://www.linkedin.com/company/olatec
- Twitter/X: https://twitter.com/OlatecThera

---

Profile page: https://yespress.io/olatec-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-07